Free Trial

Exelixis Q2 2024 Earnings Report

Exelixis logo
$35.26 -0.33 (-0.93%)
(As of 12/3/2024 ET)

Exelixis EPS Results

Actual EPS
$0.75
Consensus EPS
$0.31
Beat/Miss
Beat by +$0.44
One Year Ago EPS
N/A

Exelixis Revenue Results

Actual Revenue
$637.18 million
Expected Revenue
$468.21 million
Beat/Miss
Beat by +$168.97 million
YoY Revenue Growth
N/A

Exelixis Announcement Details

Quarter
Q2 2024
Time
N/A

Conference Call Resources

Coins Set to Soar with a Pro-Crypto White House (Ad)

Coins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over $3 Million worth of crypto – and he's not the only one at the top interested in digital assets…

Click here to reserve your free seat at the Crypto Community Summit

Exelixis Earnings Headlines

Exelixis EVP sells $2.2 million in stock
Even Trump can’t stop what’s coming.
No matter who sits in the White House over the next four years, a series of events has been triggered that could devastate millions of Americans. These events have caused five major cracks in our economy... That's why I have moved 7-figures of my own money out of the stock market.
RBC Capital Sticks to Their Buy Rating for Exelixis (EXEL)
See More Exelixis Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Exelixis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Exelixis and other key companies, straight to your email.

About Exelixis

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

View Exelixis Profile

More Earnings Resources from MarketBeat